WO2005020884A3 - Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses - Google Patents

Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses Download PDF

Info

Publication number
WO2005020884A3
WO2005020884A3 PCT/US2004/015395 US2004015395W WO2005020884A3 WO 2005020884 A3 WO2005020884 A3 WO 2005020884A3 US 2004015395 W US2004015395 W US 2004015395W WO 2005020884 A3 WO2005020884 A3 WO 2005020884A3
Authority
WO
WIPO (PCT)
Prior art keywords
viruses
nucleosides
infection
treatment
toga
Prior art date
Application number
PCT/US2004/015395
Other languages
French (fr)
Other versions
WO2005020884A2 (en
Inventor
Jean-Pierre Sommadossi
Gilles Gosselin
Colla Paolo La
Richard Storer
Original Assignee
Idenix Cayman Ltd
Centre Nat Rech Scient
Univ Cagliari
Jean-Pierre Sommadossi
Gilles Gosselin
Colla Paolo La
Richard Storer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idenix Cayman Ltd, Centre Nat Rech Scient, Univ Cagliari, Jean-Pierre Sommadossi, Gilles Gosselin, Colla Paolo La, Richard Storer filed Critical Idenix Cayman Ltd
Priority to EP04776022A priority Critical patent/EP1656093A2/en
Publication of WO2005020884A2 publication Critical patent/WO2005020884A2/en
Publication of WO2005020884A3 publication Critical patent/WO2005020884A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

This invention is in the area of methods and pharmaceutical compositions for treating a host, especially a human, infected with a coronavirus, togavirus or picornavirus, comprising administering to that host an effective amount of a compound described herein or its salt, ester or prodrug. The compound can be administered alone or in combination with another optionally substituted pentofuranonucleoside or in combination with another anti-coronavirus, anti-togavirus and/or anti-picornavirus agent.
PCT/US2004/015395 2003-05-14 2004-05-14 Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses WO2005020884A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04776022A EP1656093A2 (en) 2003-05-14 2004-05-14 Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47094903P 2003-05-14 2003-05-14
US60/470,949 2003-05-14

Publications (2)

Publication Number Publication Date
WO2005020884A2 WO2005020884A2 (en) 2005-03-10
WO2005020884A3 true WO2005020884A3 (en) 2006-06-22

Family

ID=34272426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/015395 WO2005020884A2 (en) 2003-05-14 2004-05-14 Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses

Country Status (2)

Country Link
EP (1) EP1656093A2 (en)
WO (1) WO2005020884A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299038B2 (en) 2000-05-23 2012-10-30 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US9249173B2 (en) 2006-12-28 2016-02-02 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN106573011A (en) * 2014-06-24 2017-04-19 艾丽奥斯生物制药有限公司 Substituted nucleosides, nucleotides and analogs thereof
KR102532198B1 (en) * 2012-12-21 2023-05-11 얀센 바이오파마, 인코퍼레이트. Substituted nucleosides, nucleotides and analogs thereof

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301182B6 (en) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Use of nucleoside derivatives for preparation of pharmaceutical compositions for treating infections caused by flaviviruses and pestiviruses
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
CA2734052A1 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
PL3109244T3 (en) 2004-09-14 2019-09-30 Gilead Pharmasset Llc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
PT2376088T (en) 2008-12-23 2017-05-02 Gilead Pharmasset Llc 6-o-substituted-2-amino-purine nucleoside phosphoramidates
CN102753563A (en) 2008-12-23 2012-10-24 吉利德制药有限责任公司 Nucleoside analogs
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
CN102858790A (en) 2010-03-31 2013-01-02 吉利德制药有限责任公司 Nucleoside Phosphoramidates
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
TW201329096A (en) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
MX350809B (en) 2011-12-20 2017-09-20 Riboscience Llc 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication.
MX356509B (en) 2011-12-22 2018-05-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof.
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
CA2873315A1 (en) 2012-05-22 2013-11-28 Idenix Pharamaceuticals, Inc. D-amino acid compounds for liver disease
HUE029038T2 (en) 2012-05-25 2017-01-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
US10513534B2 (en) 2012-10-08 2019-12-24 Idenix Pharmaceuticals Llc 2′-chloro nucleoside analogs for HCV infection
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
BR112014011938B1 (en) 2013-01-31 2021-03-16 Gilead Pharmasset Llc pharmaceutical composition in the form of a tablet with a fixed dose combination of two antiviral compounds, a pharmaceutical dosage form comprising said composition and use of said composition
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
EP2970357A1 (en) 2013-03-13 2016-01-20 IDENIX Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
WO2014186637A1 (en) 2013-05-16 2014-11-20 Riboscience Llc 4'-fluor0-2'-methyl substituted nucleoside derivatives
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EA201690473A1 (en) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи COMBINED COMPOSITION OF TWO ANTI-VIRUS COMPOUNDS
EP3055319A4 (en) * 2013-10-11 2018-01-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
MA41213A (en) * 2014-12-19 2017-10-24 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUES OF THEM
EP3250564B1 (en) 2015-01-30 2021-08-25 University of Maryland, Baltimore County Design synthesis and methods of use of acyclic fleximer nucleoside analogues having anti-coronavirus activity
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP3497111A2 (en) * 2016-08-12 2019-06-19 Janssen BioPharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MY197236A (en) * 2016-09-07 2023-06-07 Atea Pharmaceuticals Inc 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
BR112020005177A2 (en) * 2017-09-18 2020-09-15 Janssen Biopharma, Inc. nucleosides, nucleotides and the like substituted
US10682369B2 (en) 2017-09-21 2020-06-16 Riboscience Llc 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
CN112351799A (en) 2018-04-10 2021-02-09 阿堤亚制药公司 Treatment of HCV infected patients with cirrhosis
CN109265504B (en) * 2018-11-08 2021-07-02 河南省科学院高新技术研究中心 4-amino acid substituted pyrimidine nucleoside compound and pharmaceutical application thereof
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP3901160A1 (en) * 2020-04-25 2021-10-27 Nuvamid SA Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
JP2023522383A (en) * 2020-04-24 2023-05-30 ヌヴァミド エスアー Nicotinamide mononucleotide and nicotinamide riboside derivatives and their use in the treatment of viral infections and respiratory complications, especially caused by influenza viruses or coronaviruses
EP3912628A1 (en) * 2020-05-20 2021-11-24 Institut de Recherche en Semiochimie et Ethologie Appliquée Nucleoside analogues to inhibit the main protease of a coronavirus
EP4323362A1 (en) * 2021-04-16 2024-02-21 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880784A (en) * 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880784A (en) * 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ELDRUP ET AL: "Structure-Activity Relationship of Heterobase-Modified 2'-C-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA Replication", J. MEDICINAL CHEMISTRY, vol. 47, no. 21, 2004, pages 5284 - 5297, XP002998563 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299038B2 (en) 2000-05-23 2012-10-30 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus
US9249173B2 (en) 2006-12-28 2016-02-02 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
KR102532198B1 (en) * 2012-12-21 2023-05-11 얀센 바이오파마, 인코퍼레이트. Substituted nucleosides, nucleotides and analogs thereof
CN106573011A (en) * 2014-06-24 2017-04-19 艾丽奥斯生物制药有限公司 Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number Publication date
EP1656093A2 (en) 2006-05-17
WO2005020884A2 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
WO2005020884A3 (en) Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
WO2006110655A3 (en) Compounds, compositions and methods for the treatment of poxvirus infections
BRPI0515896A (en) a compound or a pharmaceutically acceptable salt or ester thereof, a method for treating or prophylaxis a host infected with a flavivirus, pestivirus or hepacivirus infection, and a pharmaceutical composition for treating a host infected with a flavivirus, pestivirus or hepacivirus
WO2006000922A3 (en) 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
WO2001060315A3 (en) Method for the treatment or prevention of flavivirus infections using nucleoside analogues
WO2006101538A3 (en) Andrographolide derivatives to treat viral infections
WO2004002999A8 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
EA200601467A1 (en) MACROCYCLIC COMPOUNDS AS VIRAL REPLICATION INHIBITORS
EP3042660A3 (en) Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
EA200601591A1 (en) APPLICATION OF RIBONOUSALIC COMPOUNDS FOR TREATING FLAVIVIRUS AND PESTIVIRUS INFECTIONS
EA200700362A1 (en) CONJUGAT, CONTAINING ANTI-VIRUS COMPOUND, IN PARTICULAR INHIBITING HIV, PHARMACEUTICAL COMPOSITION AND SET OF STANDARD DOSE OF THE MEDICINAL DRUG ON ITS BASIS, METHOD OF INHIBITING THE SOFTWARE PRO.
WO2005009418A3 (en) Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
WO2006130553A3 (en) Hcv protease inhibitors
EA200800932A1 (en) MODIFIED 4`-NUCLEOSIDE AS ANTI-VIRUS AGENTS
MXPA02011635A (en) Methods and compositions for treating hepatitis c virus.
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
EA200201263A1 (en) METHODS OF TREATING INFECTIONS, CAUSED BY THE HEPATITIS DELTA VIRUS, USING β-L-2'-DEOXYNUCLEOSIDES
WO2006078424A3 (en) Polyherbal compositions and methods for treating viral infections
IL195025A (en) Cyclopropyl fused indolobenzazepine derivatives and pharmaceutical compositions comprising the same as anti-hcv medicament
WO2012027712A3 (en) Potent and selective inhibitors of hepatitis c virus
WO2006050489A3 (en) Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
WO2007075695A3 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
UA91677C2 (en) Macrocyclic compounds as inhibitors of hcv replication
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004776022

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004776022

Country of ref document: EP